8-K: Ovid Therapeutics Faces Nasdaq Delisting Threat Due to Low Share Price

Ovid Therapeutics received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

Summary

• Ovid Therapeutics Inc. received a notification from Nasdaq on February 10, 2025, stating that its common stock price has fallen below the required $1.00 per share minimum for 31 consecutive trading days.
• This puts the company in non-compliance with Nasdaq Listing Rule 5450(a)(1).
• Ovid has until August 11, 2025, to regain compliance by maintaining a share price of at least $1.00 for a minimum of 10 consecutive business days.
• The company intends to monitor its share price and explore options to regain compliance.
• If Ovid fails to regain compliance, it may be eligible for an additional 180-day period by transferring its listing to the Nasdaq Capital Market, provided it meets other listing requirements.
• Failure to regain compliance or transfer to the Nasdaq Capital Market could result in delisting, which the company could appeal.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting threat, but there are potential paths to compliance.

Positives

• Ovid has the opportunity to regain compliance with Nasdaq listing requirements by August 11, 2025.
• The company may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.
• Ovid can appeal a delisting determination to a Nasdaq Hearings Panel.

Negatives

• Ovid's stock price has fallen below the $1.00 minimum required for continued listing on Nasdaq.
• The company faces potential delisting if it fails to regain compliance by the deadline.
• There is no assurance that Ovid will be able to regain compliance or that an appeal would be successful.

Risks

• Failure to regain compliance with Nasdaq listing rules could lead to delisting.
• Delisting could negatively impact the company's stock price and investor confidence.
• There is no guarantee that the company will be able to successfully appeal a delisting determination.

Future Outlook

The company intends to monitor its stock price and explore available options to regain compliance with Nasdaq listing requirements.

Industry Context

Delisting notices are common for companies with struggling stock prices, particularly in the biotechnology sector, which can be volatile. Companies often pursue reverse stock splits or other measures to boost their share price and maintain listing compliance.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining Nasdaq listing compliance.
• Companies like Cassava Sciences and Amylyx Pharmaceuticals have faced similar scrutiny regarding their stock prices and have implemented strategies to maintain their listing.
• A reverse stock split is a common strategy, but its effectiveness depends on the underlying health and prospects of the company.

Stakeholder Impact

• Shareholders may experience a decline in stock value if the company is delisted.
• Employees may face uncertainty regarding their jobs if the company's financial situation worsens.
• The company's ability to raise capital may be limited if it is delisted.

Next Steps

• Ovid Therapeutics will monitor its stock price.
• Ovid Therapeutics will explore options to regain compliance with Nasdaq listing requirements.
• Ovid Therapeutics may apply to transfer the listing of its common stock to the Nasdaq Capital Market.

Key Dates